Cutting-Edge Biologics Approvals, Trials Pick Up In Korea After New Law
Novartis among the first to benefit with approvals for Zolgensma, Kymriah, and Luxturna. The new law has also enabled its first clinical trial – a Phase Ib study by Seoul National University of a CAR-T therapy for recurrent or refractory, CD19-positive, B-cell acute lymphoblastic leukemia.
You may also be interested in...
South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.
Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.
At a recent healthcare forum in Seoul, South Korea regenerative medicine industry executives and researchers discussed the current status of the sector, as well as what policy changes and support are needed to invigorate research, development and commercialization.